Smoothened Agonist (SAG) HCl

Catalog No.S7779

For research use only.

Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.

Smoothened Agonist (SAG) HCl Chemical Structure

CAS No. 2095432-58-7

Selleck's Smoothened Agonist (SAG) HCl has been cited by 37 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Other Hedgehog/Smoothened Products

Biological Activity

Description Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
Targets
Smoothened [1]
(mouse cultured cell assay)
3 nM(EC50)
In vitro

SAG regulates Smo activity by binding directly to the Smo heptahelical bundle. [1] SAG induces Smo-dependent signaling through Gli in a GRK2-dependent way. [2] SAG also (1 nM) induces proliferation of neuronal and glial precursors without affecting the differentiation pattern of newly produced cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse Shh-Light II cell NUXYZVU2TnWwY4Tpc44h[XO|YYm= NH;XZZM1QCCqcoO= MXrBZ5RqfmG2aX;uJI9nKFOqaDDwZZRpf2G7IHnuJI1wfXOnIGPobE1NcWeqdDDJTUBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiZ3zpNUBmgHC{ZYPzbY9vKGGodHXyJFQ5KGi{czDifUBz\W6rbHzhJIx2dWmwZYPj[Y5k\SCjc4PhfUwhTUN3ME2wMlAxQDhizszN Ml3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OEW5OVgoRjJ{OUi1PVU5RC:jPh?=
HUVEC NIPnTlREgXSxdH;4bYNqfHliYYPzZZk> NYrwe4tUOjRiaB?= MnHuR5l1d3SxeHnjbZR6KGGpYXnud5QhUFWYRVOgZYZ1\XJiMkSgbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUKyJO69VQ>? NGDWPYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm4OVk2QCd-MkK5PFU6PTh:L3G+
Shh-Light II NXPBVmsxTnWwY4Tpc44h[XO|YYm= MkfXOFghcHK| M33tRmFkfGm4YYTpc44hd2ZiU3joJJBifGi5YYmgbY4hdW:3c3WgV4hpNUyrZ3j0JGlKKGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDncIkyKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KHKnbnnscIEhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC5yNkG4JO69VS5? M3S4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUi1PVU5Lz5{Mkm4OVk2QDxxYU6=
NIH/3T3 NXHnbHRGTnWwY4Tpc44h[XO|YYm= M3T3UmFod26rc4SgZYN1cX[rdImgZZQhW22xIHnuJI1wfXOnIF7JTE8{XDNiY3XscJMhfHKjboPm[YN1\WRid3n0bEBIdGlvZHXw[Y5l\W62IH\pdoVndHlibIXjbYZmemG|ZTDy[ZBwenSncjDhd5Nme3OnZDDhd{B{fGmvdXzheIlwdiCxZjDHcIkhfHKjboPjdolxfGmxbjDmZYN1d3JuIFXDOVAhRSByLkCzJO69VS5? M4TnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEK5NlU2Lz5{N{SyPVI2PTxxYU6=
C3H10T1/2 NWT0W5IzTnWwY4Tpc44h[XO|YYm= NX\vSpJGPiCmYYnz MXLB[49vcXO2IHHjeIl3cXS7IHH0JHNudyCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJINmdGxiZHnm[oVz\W62aXH0bY9vKGmwdH:gc5N1\W:kbHHzeEBqdmO3YnH0[YQh\m:{IE[g[IF6eyCkeTDhcItidGmwZTDwbI9{eGijdHHz[UBie3OjeTygSWM2OCB;IECuNVMh|ryPLh?= NEi4eoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SyPVI2PSd-Mke0NlkzPTV:L3G+
A673 MljrdWhVWyCjc4PhfS=> NGewWWZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MmflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 MlvVdWhVWyCjc4PhfS=> MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NV7iW5dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MU\xTHRUKGG|c3H5 Mn;NdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| Ml7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NH7KUIVyUFSVIHHzd4F6 NGrNS|dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NV3QNIpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M1zZc5FJXFNiYYPzZZk> NX:3RWxueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> Moj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NXfEdHpleUiWUzDhd5NigQ>? NFfYTGlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= NUe3SnVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) NV62b|BpeUiWUzDhd5NigQ>? Mnm4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NXixbmh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 M4LOcZFJXFNiYYPzZZk> NFHhN2VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NH7z[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NYK3O5FCeUiWUzDhd5NigQ>? MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NGTZe289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 M4fyUJFJXFNiYYPzZZk> MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MXzxTHRUKGG|c3H5 MknEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= Ml:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 M2[zeZFJXFNiYYPzZZk> M{LjWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NYLFOllXeUiWUzDhd5NigQ>? MlTUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? M3nkcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Assay
Methods Test Index PMID
Western blot LC3I / LC3II 23504944
Immunofluorescence Smo ; acetylated alpha tubulin 25636740 25992706
In vivo In the adult rat hippocampus, the intracerebroventricular administration of SAG (2.5 nM) significantly increases the number of newly generated cells and extends survival of hippocampal cells. [3] In mice, SAG (20 μg/g, i.p.) effectively prevents GC-induced neonatal cerebellar developmental abnormalities. [4]

Protocol (from reference)

Animal Research:[3]
  • Animal Models: Rat
  • Dosages: 2.5 nM
  • Administration: Intracerebroventricular administration
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 100 mg/mL
(189.92 mM)
DMSO 71 mg/mL warmed
(134.84 mM)
Ethanol 40 mg/mL warmed
(75.97 mM)

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.

100mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 526.52
Formula

C28H29Cl2N3OS

CAS No. 2095432-58-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(C5=CC=CC=C5S4)Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03645044 Active not recruiting -- Hiv|HBV Coinfection University of Melbourne|National Health and Medical Research Council Australia|The University of Western Australia|University of Adelaide|The HIV Netherlands Australia Thailand Research Collaboration|University of Malaya|YR Gaitonde Centre for AIDS Research and Education|Melbourne Health May 24 2018 --
NCT03180619 Completed Drug: TAF Chronic Hepatitis B Gilead Sciences June 29 2017 Phase 2
NCT02195518 Completed Drug: Tenofovir disoproxil fumarate Hepatitis B Chronic GlaxoSmithKline March 18 2015 Phase 4

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Smoothened Agonist|Smoothened Agonist ic50|Smoothened Agonist price|Smoothened Agonist cost|Smoothened Agonist solubility dmso|Smoothened Agonist purchase|Smoothened Agonist manufacturer|Smoothened Agonist research buy|Smoothened Agonist order|Smoothened Agonist mouse|Smoothened Agonist chemical structure|Smoothened Agonist mw|Smoothened Agonist molecular weight|Smoothened Agonist datasheet|Smoothened Agonist supplier|Smoothened Agonist in vitro|Smoothened Agonist cell line|Smoothened Agonist concentration|Smoothened Agonist nmr|Smoothened Agonist in vivo|Smoothened Agonist clinical trial|Smoothened Agonist inhibitor|Smoothened Agonist Stem Cells & Wnt inhibitor